e-learning
resources
Berlin 2001
Monday 24.09.2001
Rare and unusual diseases or problems
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
DLCO change in systemic sclerosis patients after prostaglandin E1 infusion: preliminary data
B. Barbara, S. Centanni, F. Di Marco, M. Massarotti, C. Regorda, P. Carlucci, B. Marasini (Milan, Italy)
Source:
Annual Congress 2001 - Rare and unusual diseases or problems
Session:
Rare and unusual diseases or problems
Session type:
Thematic Poster Session
Number:
1528
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Barbara, S. Centanni, F. Di Marco, M. Massarotti, C. Regorda, P. Carlucci, B. Marasini (Milan, Italy). DLCO change in systemic sclerosis patients after prostaglandin E1 infusion: preliminary data. Eur Respir J 2001; 16: Suppl. 31, 1528
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Fluid challenge test and pulmonary haemodynamics in patients with systemic sclerosis
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Quality of spirometry and diffusion of the lung (DLCO) data in patients with systemic sclerosis.
Source: International Congress 2019 – Insights into physiological diagnostic services
Year: 2019
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2)
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020
Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis
Source: Eur Respir J 2016; 48: 1658-1667
Year: 2016
Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Plasma 6-ketoPGF1α, a stable metabolite of prostaglandin I2 shows a marked decrease in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 651s
Year: 2006
Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
Source: Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020
Year: 2020
Pulmonary involvement and exercise limitation in patients with systemic sclerosis
Source: Eur Respir J 2004; 24: Suppl. 48, 53s
Year: 2004
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS)
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
A preliminary study to identify correlations between blood glucose levels and cardiorespiratory observations in acute asthma patients receiving nebulised salbutamol.
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 62s
Year: 2004
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Protective effects of salmeterol on impeded alveolar-capillary gas transfer with saline infusion in COPD patients: preliminary results
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept